Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.008 USD | 0.00% | -20.00% | -63.64% |
Feb. 22 | Baudax Bio, Inc. Filed for Bankruptcy | CI |
2023 | Baudax Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
Financials (USD)
Sales 2021 | 1.08 | Sales 2022 | 1.27 | Capitalization | 1.76M |
---|---|---|---|---|---|
Net income 2021 | -19M | Net income 2022 | -58M | EV / Sales 2021 | 17,166,252 x |
Net cash position 2021 | 6.35 | Net Debt 2022 | 2.68 | EV / Sales 2022 | 1,390,484 x |
P/E ratio 2021 |
-0.76
x | P/E ratio 2022 |
-0.02
x | Employees | 9 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 99.98% |
Latest transcript on Baudax Bio, Inc.
1 day | -37.30% | ||
1 week | -20.00% | ||
Current month | -20.00% | ||
1 month | -24.53% | ||
3 months | -60.40% | ||
6 months | -90.60% | ||
Current year | -63.64% |
Managers | Title | Age | Since |
---|---|---|---|
Gerri Henwood
CEO | Chief Executive Officer | 71 | 18-12-31 |
Natalie McAndrew
DFI | Director of Finance/CFO | 50 | 23-10-08 |
Diane Myers
PRN | Corporate Officer/Principal | 60 | 19-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 83 | 19-11-20 | |
Gerri Henwood
CEO | Chief Executive Officer | 71 | 18-12-31 |
Wayne Weisman
CHM | Chairman | 68 | 19-11-20 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-20 | 0.008 | 0.00% | 2 031 |
24-05-17 | 0.008 | -37.30% | 66,150 |
24-05-16 | 0.0128 | +59.50% | 10,022 |
24-05-15 | 0.008 | +12.68% | 100,756 |
24-05-14 | 0.0071 | -29.00% | 11,698 |
Delayed Quote OTC Markets, May 17, 2024 at 03:59 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-63.64% | 420K | |
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B |
- Stock Market
- Equities
- BXRXQ Stock